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Watanabe, Minyu Lai, Kazuhide Hamasaki, Fumikazu Kohi, Koichi Kitajima,
Ikuro Kimura, Tomiro Adachi, Seiichi Yorimitsu, Masaaki Tokioka, and Hiroshi
Sanada
Abstract
Relapses in nine patients with acute myelocytic leukemia were treated with a combination of
aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily
by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses,
was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the
bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the
resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%). The
time required for achieving the complete remission varied from 20 to 55 days with a median of
39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks.
Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients,
although they were managed by symptomatic treatment. The results indicate the effectiveness of
this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.
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